Sign in:
Email
 Password  save:
  
 Company Reports 
 
   
My Recent Searches
  Help
 
   
 
 
 
  
   
Insider Information:   Foehr Matthew W
Relationship:   President and CEO, Dir...
City:   Palo Alto
State:   CA
   
Insider Summary:
  
   
Companies Owned :   4    
Direct Shares   3,948,737    

Indirect Shares

  0      
Direct Value   $33,186,682    

Indirect Value

  $0      
Total Shares   3,948,737      
Total Value   $33,186,682      


Ligand Pharmaceuticals Inc
 $12,968,473 Viking Therapeutics, Inc.
 $5,798,350 Qualigen Therapeutics Inc
 $60,999 OmniAb, Inc
 $14,358,860 Ligand Pharmaceuticals Inc
 $12,968,473 Viking Therapeutics, Inc.
 $5,798,350 Qualigen Therapeutics Inc
 $60,999 OmniAb, Inc
 $14,358,860
 


Historical Performance :
Based on 6 Month Return Percentages
Buys 
Sells 

     Total Filings :

    13   
    4    

     Stock price went up :

    6   
    0    
     Stock price went down :
    7   
    4    
   
     Gain/Loss Ratio :
   0.0   
   -4.0   
     Percentage Gain/Loss :
   32.7%
 -89.3%
     
   
Holdings :
     Menu Company Name Ticker Relation Direct Date Direct Shares Indirect Date Indirect Shares Total Value Sold  
            Ligand Pharmaceuticals Inc LGND Former Executive Officer 2022-11-01 162,187 2011-04-18 0    Premium*  
            Viking Therapeutics, Inc. VKTX Director 2022-05-02 111,250 2015-05-04 0    Premium*  
            Qualigen Therapeutics Inc QLGN Director 2020-04-10 138,635 2015-06-24 0    Premium*  
            OmniAb, Inc OABI President and CEO, Dir... 2024-05-24 3,536,665 2022-11-01 0    Premium*  
* Premium Members only  

Records found :    136         Free Registration Required For Full Results.    Limit: 25

Download
  Page 4 of 6
Ticker Company Name Relation   Off-Dir-10% Trans. Date Form Action Price Mkt Value D/I Shares    Holdings   
Rank

 
3m +/-  
Form
LGND Ligand Pharmaceuticals In... President and COO   •       –      –    2017-03-02 4 S $103.39 $711,214 D/D (6,879) 90,720 0 -
LGND Ligand Pharmaceuticals In... President and COO   •       –      –    2017-03-03 4 OE $9.97 $19,940 D/D 2,000 92,720 0 -
LGND Ligand Pharmaceuticals In... President and COO   •       –      –    2017-05-12 4 S $112.20 $630,650 D/D (5,621) 92,720 0 -
LGND Ligand Pharmaceuticals In... President and COO   •       –      –    2017-05-12 4 OE $9.97 $56,041 D/D 5,621 98,341 0 -
LGND Ligand Pharmaceuticals In... President and COO   •       –      –    2017-05-15 4 OE $9.97 $21,934 D/D 2,200 94,920 0 -
LGND Ligand Pharmaceuticals In... President and COO   •       –      –    2017-08-09 4 S $127.51 $777,824 D/D (6,100) 94,920 0 -
LGND Ligand Pharmaceuticals In... President and COO   •       –      –    2017-08-09 4 OE $9.97 $69,292 D/D 6,950 95,770 0 -
LGND Ligand Pharmaceuticals In... President and COO   •       –      –    2017-12-28 4 A $0.00 $0 D/D 5,695 101,465 0 -
LGND Ligand Pharmaceuticals In... President and COO   •       –      –    2017-12-28 4 D $138.66 $411,959 D/D (2,971) 98,494 0 -
LGND Ligand Pharmaceuticals In... President and COO   •       –      –    2018-02-15 4 D $157.18 $575,750 D/D (3,663) 94,831 0 -
LGND Ligand Pharmaceuticals In... President and COO   •       –      –    2018-02-23 4 S $152.98 $832,824 D/D (5,444) 95,835 0 -
LGND Ligand Pharmaceuticals In... President and COO   •       –      –    2018-02-23 4 OE $9.97 $88,785 D/D 6,448 101,279 0 -
LGND Ligand Pharmaceuticals In... President and COO   •       –      –    2018-03-02 4 A $0.00 $0 D/D 3,883 99,718 0 -
LGND Ligand Pharmaceuticals In... President and COO   •       –      –    2018-03-06 4 D $165.87 $241,673 D/D (1,457) 101,201 0 -
LGND Ligand Pharmaceuticals In... President and COO   •       –      –    2018-03-06 4 A $0.00 $0 D/D 2,940 102,658 0 -
LGND Ligand Pharmaceuticals In... President and COO   •       –      –    2018-05-10 4 S $167.63 $1,488,687 D/D (8,881) 101,201 0 -
LGND Ligand Pharmaceuticals In... President and COO   •       –      –    2018-05-10 4 OE $9.97 $139,026 D/D 9,936 102,256 0 -
LGND Ligand Pharmaceuticals In... President and COO   •       –      –    2018-09-04 4 AS $255.01 $3,060,082 D/D (12,000) 103,300 0 -
LGND Ligand Pharmaceuticals In... President and COO   •       –      –    2018-09-04 4 OE $9.97 $184,049 D/D 13,044 115,300 0 -
LGND Ligand Pharmaceuticals In... President and COO   •       –      –    2018-10-01 4 AS $273.88 $3,286,560 D/D (12,000) 105,388 0 -
LGND Ligand Pharmaceuticals In... President and COO   •       –      –    2018-10-01 4 OE $9.97 $194,457 D/D 14,088 117,388 0 -
LGND Ligand Pharmaceuticals In... President and COO   •       –      –    2018-12-12 4 OE $9.97 $79,750 D/D 7,999 113,387 0 -
LGND Ligand Pharmaceuticals In... President and COO   •       –      –    2019-01-23 4 A $0.00 $0 D/D 7,262 119,365 0 -
LGND Ligand Pharmaceuticals In... President and COO   •       –      –    2019-01-23 4 D $111.78 $287,051 D/D (2,568) 118,081 0 -
LGND Ligand Pharmaceuticals In... President and COO   •       –      –    2019-02-11 4 A $0.00 $0 D/D 7,472 125,553 0 -

  136  Records found
  1   2   3   4  5   6      
  Page 4 of 6  
 
Free Registration Required For Full Results.    Limit: 25

 
 
  Transaction Code Key: Ownership Code Key
  B - Buy AB - Automatic Buy D - Direct Ownership
  S - Sell AS - Automatic Sell I - Indirect Ownership
OE - Options Exercised A - Aquired
  IO - Initital Ownership D - Disposed